Tea Galic1, Josko Bozic2, Natalija Ivkovic3, Grgo Gunjaca4, Tina Kurir Ticinovic2, Zoran Dogas5,6. 1. Study of Dental Medicine, University of Split School of Medicine, Soltanska 2, Split, Croatia. 2. Department of Pathophysiology, University of Split School of Medicine, Soltanska 2, Split, Croatia. 3. Split Sleep Medicine Center, University of Split School of Medicine, Soltanska 2, Split, Croatia. 4. Department of Pharmacology, University of Split School of Medicine, Soltanska 2, Split, Croatia. 5. Split Sleep Medicine Center, University of Split School of Medicine, Soltanska 2, Split, Croatia. zdogas@mefst.hr. 6. Department of Neuroscience, University of Split School of Medicine, Soltanska 2, 21000, Split, Croatia. zdogas@mefst.hr.
Abstract
STUDY OBJECTIVES: An independent association between obstructive sleep apnea (OSA) and cardiovascular events has been reported, suggesting that OSA may lead to cardiometabolic dysregulation. We prospectively investigated the effect of mandibular advancement device (MAD) treatment on arterial stiffness, glucose metabolism, and certain inflammatory markers as predictors of cardiometabolic risk in mild to moderate OSA patients. METHODS: A total of 18 patients with mild to moderate OSA were prospectively enrolled in the study to determine the effects of MAD treatment at 3 months and 1 year following initiation of the treatment. Sleep studies, arterial stiffness assessment, and laboratory analyses were obtained at the baseline and at the time of follow-up. The data collected at 1 year were compared to baseline values. RESULTS: There was a significant decrease in apnea-hypopnea index (AHI) after 1 year of treatment when compared to baseline (22.9 ± 5.9 to 9.7 ± 4.5, P < 0.001). Furthermore, MAD treatment was associated with reduced levels of fasting plasma glucose values after 1 year of treatment (5.3 ± 0.5 to 4.9 ± 0.5 mmol/L, P < 0.001), as well as fasting plasma insulin values (14.1 ± 7.8 to 10.9 ± 6.4 μU/mL, P < 0.05) and HOMA-IR (3.3 ± 1.8 to 2.4 ± 1.4, P < 0.001). There was significant improvement in pulse wave velocity (9.3 ± 1.9 m/s at baseline to 8.1 ± 1.7 m/s, P < 0.05) after 1 year of treatment. Plasma level of an inflammatory marker fibrinogen decreased significantly from 3.4 ± 0.7 at baseline to 3.0 ± 0.9, (P < 0.05) at 1-year follow-up. CONCLUSIONS: The MAD treatment improved arterial stiffness, glucose metabolism, and insulin resistance in mild to moderate OSA patients after 1 year of treatment.
STUDY OBJECTIVES: An independent association between obstructive sleep apnea (OSA) and cardiovascular events has been reported, suggesting that OSA may lead to cardiometabolic dysregulation. We prospectively investigated the effect of mandibular advancement device (MAD) treatment on arterial stiffness, glucose metabolism, and certain inflammatory markers as predictors of cardiometabolic risk in mild to moderate OSA patients. METHODS: A total of 18 patients with mild to moderate OSA were prospectively enrolled in the study to determine the effects of MAD treatment at 3 months and 1 year following initiation of the treatment. Sleep studies, arterial stiffness assessment, and laboratory analyses were obtained at the baseline and at the time of follow-up. The data collected at 1 year were compared to baseline values. RESULTS: There was a significant decrease in apnea-hypopnea index (AHI) after 1 year of treatment when compared to baseline (22.9 ± 5.9 to 9.7 ± 4.5, P < 0.001). Furthermore, MAD treatment was associated with reduced levels of fasting plasma glucose values after 1 year of treatment (5.3 ± 0.5 to 4.9 ± 0.5 mmol/L, P < 0.001), as well as fasting plasma insulin values (14.1 ± 7.8 to 10.9 ± 6.4 μU/mL, P < 0.05) and HOMA-IR (3.3 ± 1.8 to 2.4 ± 1.4, P < 0.001). There was significant improvement in pulse wave velocity (9.3 ± 1.9 m/s at baseline to 8.1 ± 1.7 m/s, P < 0.05) after 1 year of treatment. Plasma level of an inflammatory marker fibrinogen decreased significantly from 3.4 ± 0.7 at baseline to 3.0 ± 0.9, (P < 0.05) at 1-year follow-up. CONCLUSIONS: The MAD treatment improved arterial stiffness, glucose metabolism, and insulin resistance in mild to moderate OSA patients after 1 year of treatment.
Authors: Clete A Kushida; Michael R Littner; Timothy Morgenthaler; Cathy A Alessi; Dennis Bailey; Jack Coleman; Leah Friedman; Max Hirshkowitz; Sheldon Kapen; Milton Kramer; Teofilo Lee-Chiong; Daniel L Loube; Judith Owens; Jeffrey P Pancer; Merrill Wise Journal: Sleep Date: 2005-04 Impact factor: 5.849
Authors: Rodrigo P Pedrosa; Isly M L Barros; Luciano F Drager; Marcio S Bittencourt; Ana Kelley L Medeiros; Liana L Carvalho; Thais C Lustosa; Martinha M B Carvalho; Moacir N L Ferreira; Geraldo Lorenzi-Filho; Laura O B F Costa Journal: Chest Date: 2014-07 Impact factor: 9.410
Authors: Kate Sutherland; Olivier M Vanderveken; Hiroko Tsuda; Marie Marklund; Frederic Gagnadoux; Clete A Kushida; Peter A Cistulli Journal: J Clin Sleep Med Date: 2014-02-15 Impact factor: 4.062
Authors: Mark Butlin; Ahmad Qasem; Francesca Battista; Erwan Bozec; Carmel M McEniery; Eugénie Millet-Amaury; Giacomo Pucci; Ian B Wilkinson; Giuseppe Schillaci; Pierre Boutouyrie; Alberto P Avolio Journal: J Hypertens Date: 2013-11 Impact factor: 4.844